全球首个卒中后遗症与帕金森病细胞治疗技术获批临床转化应用

Core Viewpoint - The newly approved olfactory sheath cell therapy technology in China represents a significant advancement in the treatment of stroke sequelae and Parkinson's disease, marking the transition from research to clinical application in the field of neurodegenerative diseases [1][2]. Group 1: Technology Approval and Clinical Application - The olfactory sheath cell therapy has received official approval for clinical application by the National Health Industry Demonstration Zone in Beidaihe, indicating China's leadership in the field of cell therapy for neurological disorders [1]. - This therapy is based on two multi-center, randomized, double-blind, placebo-controlled Phase II clinical trials, demonstrating its safety and efficacy for patients with advanced ischemic stroke and Parkinson's disease [2]. Group 2: Historical Context and Development - The development of this technology can be traced back to 2001 when Professor Huang Hongyun's team first applied olfactory sheath cell technology to treat patients with complete late-stage spinal cord injuries, achieving significant functional recovery [5]. - The successful transition of this technology into clinical practice is attributed to the collaboration between the Beidaihe Rehabilitation Hospital and Professor Huang's team, as well as the supportive policies in the Beidaihe National Life and Health Industry Demonstration Zone [5]. Group 3: Future Implications and Treatment Paradigm Shift - Olfactory sheath cell therapy is considered one of the most effective clinical techniques for repairing central nervous system injuries, and it can be combined with other methods such as neural modulation and neuro-rehabilitation training for comprehensive treatment [5]. - The concept of "comprehensive neural repair treatment" proposed by Professor Huang's team signifies a shift in the treatment paradigm for neurological diseases from traditional symptomatic management to structural and functional repair [5].